Instil Bio IncNASDAQ:TIL
- LAST PRICE66.9750
- TODAY'S CHANGE (%)-1.3850 (-2.0260%)
- Bid / Lots66.9100/ 2
- Ask / Lots67.4700/ 1
- Open / Previous Close68.3600 / 68.3600
- Day Range
- 52 Week Range
- Volume32,019
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | TIL |
|---|---|---|
| 09:32 ET | 587 | 68.36 |
| 09:39 ET | 100 | 68.4885 |
| 09:41 ET | 300 | 68.5 |
| 09:52 ET | 200 | 68.22 |
| 09:54 ET | 800 | 68.03 |
| 09:56 ET | 261 | 68.8338 |
| 09:59 ET | 478 | 68.9 |
| 10:01 ET | 340 | 67.95 |
| 10:06 ET | 100 | 68.64 |
| 10:08 ET | 200 | 68.3726 |
| 10:10 ET | 716 | 68.7 |
| 10:21 ET | 484 | 67.7501 |
| 10:24 ET | 200 | 67.7501 |
| 10:37 ET | 450 | 68.52 |
| 10:48 ET | 100 | 68.2201 |
| 10:53 ET | 2583 | 69.46 |
| 10:55 ET | 586 | 69.7021 |
| 11:02 ET | 1990 | 70.135 |
| 11:06 ET | 587 | 68.9648 |
| 11:08 ET | 500 | 69.2 |
| 11:11 ET | 100 | 69.83 |
| 11:13 ET | 500 | 69.62 |
| 11:20 ET | 100 | 69.06 |
| 11:26 ET | 300 | 68.66 |
| 11:31 ET | 300 | 68.34 |
| 11:33 ET | 349 | 68.16 |
| 11:40 ET | 100 | 67.99 |
| 11:42 ET | 400 | 67.665 |
| 11:44 ET | 472 | 67.36 |
| 11:47 ET | 2474 | 66.5 |
| 11:49 ET | 1100 | 67.02 |
| 11:51 ET | 1100 | 67.25 |
| 11:56 ET | 795 | 67.23 |
| 11:58 ET | 400 | 67.135 |
| 12:00 ET | 400 | 66.975 |
Sep 17, 2024
DJ Instil Bio Price Target Maintained With a $120.00/Share by HC Wainwright & Co., from 7:11AM ET on Tuesday Sep 17, 2024 by Dow Jones
7:11AM ET on Tuesday Sep 17, 2024 by Dow Jones
Sep 16, 2024
DJ Instil Bio Is Maintained at Buy by HC Wainwright & Co., from 1:34PM ET on Monday Sep 16, 2024 by Dow Jones
1:34PM ET on Monday Sep 16, 2024 by Dow JonesDJ Instil Bio Price Target Maintained With a $180.00/Share by Baird, from 10:33AM ET on Monday Sep 16, 2024 by Dow Jones
10:33AM ET on Monday Sep 16, 2024 by Dow JonesInstil Bio and ImmuneOnco Announce Global Registrational Strategy for PD-L1xVEGF Bispecific Antibody, SYN-2510/IMM2510, in Non-Small Cell Lung Cancer and Triple-Negative Breast Cancer, from 6:00AM ET on Monday Sep 16, 2024 by Dow Jones
6:00AM ET on Monday Sep 16, 2024 by Dow Jones
Sep 13, 2024
DJ Instil Bio Up Nearly 62%, on Pace for Record Percent Increase -- Data Talk, from 2:19PM ET on Friday Sep 13, 2024 by Dow Jones
2:19PM ET on Friday Sep 13, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Instil Bio Inc | 444.6M | -3.6x | --- |
Aura Biosciences Inc | 447.0M | -5.2x | --- |
Kalvista Pharmaceuticals Inc | 432.2M | -3.4x | --- |
Prime Medicine Inc | 427.3M | -1.6x | --- |
Tectonic Therapeutic Inc | 421.1M | -1.7x | --- |
Compass Pathways PLC | 472.6M | -3.0x | --- |
Company Information
Instil Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies. The Company seeks to in-license/acquire and develop novel therapeutic candidates in diseases with significant unmet medical need. Its first such program is an engineered tumor infiltrating lymphocyte (TIL), cell therapy for the treatment of cancer. It is engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor (CoStAR), platform. The Company's lead CoStAR-TIL product candidate, ITIL-306, expresses a CoStAR molecule designed to recognize folate receptor alpha (Fra), a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC and renal cancer. CAR-T and TCR-T therapies are cell products composed of T cells that have been genetically engineered to recognize a specific cancer-related antigen on the surface of tumor cells.
Contact Information
- Headquarters
- 3963 Maple Avenue, Suite 350DALLAS, TX, United States 75219
- Phone
- 972-499-3350
- Fax
- 302-531-3150
Executives
- Chairman of the Board, Chief Executive Officer
- Bronson Crouch
- Chief Financial Officer, Chief Business Officer
- Sandeep Laumas
- Lead Independent Director
- Neil Gibson
- Independent Director
- Gwendolyn Binder-Scholl
- Independent Director
- George Matcham
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $444.6M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 6.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.51 |
EPS | $-18.39 |
Book Value | $34.72 |
P/E Ratio | -3.6x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
